For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
|Sample type||Average %||Range|
|Cell culture supernatant||97.35||89% - 106%|
|Serum||95.46||86% - 104%|
|Plasma||96.47||88% - 103%|
Abcam’s VEGF Receptor 3 Human ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of Human VEGF Receptor 3 in serum, plasma, and cell culture supernatants.
This assay employs an antibody specific for Human VEGF Receptor 3 coated on a 96-well plate. Standards and samples are pipetted into the wells and VEGF Receptor 3 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Human VEGF Receptor 3 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of VEGF Receptor 3 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
Optimization may be required with urine samples.
|Components||1 x 96 tests|
|200X HRP-Streptavidin Concentrate||1 x 200µl|
|20X Wash Buffer Concentrate||1 x 25ml|
|5X Assay Diluent B||1 x 15ml|
|Assay Diluent A||1 x 30ml|
|Biotinylated anti-Human VEGF Receptor 3||2 vials|
|Recombinant Human VEGF Receptor 3 Standard (lyophilized)||2 vials|
|Stop Solution||1 x 8ml|
|TMB One-Step Substrate Reagent||1 x 12ml|
|VEGF Receptor 3 Microplate (12 x 8 wells)||1 unit|
Our Abpromise guarantee covers the use of ab100666 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Sandwich ELISA||Use at an assay dependent concentration.|
ab100666 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"